{"id":2102090,"date":"2023-11-17T15:31:01","date_gmt":"2023-11-17T20:31:01","guid":{"rendered":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/popular-obesity-drugs-could-be-sold-in-pill-form-as-soon-as-next-year\/"},"modified":"2023-11-17T15:34:51","modified_gmt":"2023-11-17T20:34:51","slug":"popular-obesity-drugs-could-be-sold-in-pill-form-as-soon-as-next-year","status":"publish","type":"post","link":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/popular-obesity-drugs-could-be-sold-in-pill-form-as-soon-as-next-year\/","title":{"rendered":"Popular obesity drugs could be sold in pill form as soon as next year"},"content":{"rendered":"<aside class=\"mashsb-container mashsb-main mashsb-stretched\"><div class=\"mashsb-box\"><div class=\"mashsb-count mash-medium\" style=\"&quot;\"><div class=\"counts mashsbcount\">28<\/div><span class=\"mashsb-sharetext\">SHARES<\/span><\/div><div class=\"mashsb-buttons\"><a class=\"mashicon-facebook mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fwww.conservativenewsdaily.net%2Fbreaking-news%2Fpopular-obesity-drugs-could-be-sold-in-pill-form-as-soon-as-next-year%2F\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Facebook<\/span><\/a><a class=\"mashicon-twitter mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/twitter.com\/intent\/tweet?text=&amp;url=https:\/\/www.conservativenewsdaily.net\/breaking-news\/?p=2102090&amp;via=ConservNewsDly\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Twitter<\/span><\/a><a class=\"mashicon-subscribe mash-medium mash-nomargin mashsb-noshadow\" href=\"#\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Subscribe<\/span><\/a><div class=\"onoffswitch2 mash-medium mashsb-noshadow\" style=\"display:none\"><\/div><\/div>\n            <\/div>\n                <div style=\"clear:both\"><\/div><\/aside>\n            <!-- Share buttons by mashshare.net - Version: 4.0.47--><h2>Pharmaceutical Giants Racing to Develop Pill Versions of Weight Loss Medications<\/h2>\n<p>Exciting news for those struggling \u2064with obesity: Novo Nordisk and Eli Lilly, two\u200c leading\u200b pharmaceutical companies,\u200d are on track\u2064 to release pill versions of their highly\u2063 sought-after <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/doctors-say-these-are-the-four-most-effective-weight-loss-drugs\/\" title=\"Doctors Say These Are the Four Most Effective Weight-loss Drugs\">weight loss medications<\/a> as early as next year. These new \u2062options will greatly expand the range of treatments \u2064available for \u200dobesity.<\/p>\n<p>Novo&#8217;s semaglutide and \u200dLilly&#8217;s orforglipron\u2062 pills are currently in \u2062the advanced\u2063 stage three of clinical trials and have already shown promising results. Similar to their injection-based counterparts, such as Ozempic \u200dand Wegovy, these pills work by mimicking the GLP-1 \u2063hormone, which <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/you-can-lower-your-heart-risk-by-eating-at-this-time\/\" title=\"You Can Lower Your Heart Risk By Eating at This Time\">helps people feel full<\/a>.<\/p>\n<p>What makes \u200bthese pill \u2063versions particularly appealing is their cost-effectiveness and\u200d ease \u200dof production. Unlike injectables, which require refrigeration to \u200dmaintain their \u200befficacy, small\u200d molecule pills can \u200cbe manufactured in larger quantities \u2062due \u2064to their simpler chemical structure. This\u200d makes them more accessible in areas \u2063without reliable refrigeration.<\/p>\n<p>Despite \u2062the advantages in\u2063 production costs,\u200c the list price of Novo&#8217;s pill version, Rybelsus, remains\u2063 high \u2063at $936 per month without \u2062insurance. However, a high-dose Rybelsus specifically\u2062 designed for weight loss\u2062 is currently under\u2062 review in Europe,\u2064 with \u200d<a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/popular-obesity-drugs-could-be-sold-in-pill-form-as-soon-as-next-year\/\" title=\"Popular obesity drugs could be sold in pill form as soon as next year\">late-stage trials showing<\/a> a remarkable 15% reduction in body weight within 16 months.<\/p>\n<p>While there have been reports\u200b of\u2064 more gastrointestinal \u200bside\u200d effects with the oral medication\u2062 compared to \u2063the injectable version, experts believe this \u2063may be due to the drug&#8217;s method of\u2062 action. Taking Rybelsus on an empty stomach for \u200cproper absorption can cause stomach pains and discomfort, similar to any medication taken without food.<\/p>\n<p>The success of Novo \u200band Lilly has\u200b attracted the \u200dattention of competitors Pfizer and AstraZeneca,\u2064 who are also eager to enter\u2064 the \u200dweight loss \u200bdrug \u200bmarket. With the market projected to reach $100 billion within seven years, \u200bthe future looks promising for those seeking effective obesity treatments.<\/p>\n<p>Angela Fitch, a representative from the Obesity Medicine Association, expressed excitement about the increasing variety of treatment options for obesity. She emphasized that obesity is \u2064a complex condition with diverse underlying causes, and having more choices \u200dwill\u2062 allow for personalized and effective treatment \u2062plans.<\/p>\n<p>Despite\u200b the proven benefits of weight loss \u2063medications \u200clike\u2063 semaglutide in reducing the\u200d risk of cardiovascular\u200d death, most health insurance plans do\u200d not cover them. Fitch believes this is \u2064due \u200cto the mischaracterization \u200bof these drugs as mere &#8220;vanity\u200d weight loss drugs.&#8221; She urges a shift\u2063 in \u2064perspective, \u200cemphasizing that these medications are about improving health, not just shedding \u2064pounds.<\/p>\n<p>Recognizing the urgent need for expanded access to weight management drugs, bipartisan legislation \u200chas \u200bbeen introduced in Congress to incorporate coverage \u200cunder Medicare. This move is supported by physicians\u2063 like Sen. Bill Cassidy, Rep. Brad Wenstrup, and Rep. Raul Ruiz, who\u2064 highlight the staggering costs \u2062of obesity to the Medicare program.<\/p>\n<p>According to the National Institutes of Health, two in five\u200c Americans can\u200d be diagnosed with obesity, and\u2064 approximately one in three meet the medical definition of overweight. With \u2064the\u2064 development of new pill versions and\u2062 the potential\u2063 for increased coverage, there is \u200chope for\u200b a brighter future in \u200cthe fight \u200dagainst obesity.<\/p>\n<p><strong>Click here to read more\u200c from the Washington \u200cExaminer.<\/strong><\/p>\n<p> <\/p>\n<h2> \u2064What role do pill versions of weight loss medications play in a comprehensive approach to obesity treatment, and how should\u2062 their benefits and potential risks be evaluated<\/h2>\n<p><span>  Delivery rather than \u2062its\u2062 chemical composition. The pills are designed to\u2064 be taken once\u200b daily, allowing for a more convenient and \u200cdiscreet method of medication administration.<\/p>\n<p>The development \u2063of pill versions\u200b of weight loss medications is a significant advancement \u200cin the \u200dfield of obesity\u2062 treatment. According to the World Health Organization, obesity has tripled worldwide since 1975, and approximately 39% of adults \u2063aged 18 years and over were\u200d overweight in 2016. This alarming statistic highlights the urgent need \u2062for effective and accessible weight loss solutions.<\/p>\n<p>Weight loss medications are typically\u200c prescribed in conjunction with lifestyle modifications, such as\u200b exercise and a healthy diet. They\u200d are intended for individuals who have a body mass index (BMI) of 30 or higher,\u2064 or those with \u200da \u200cBMI of 27 or higher with obesity-related conditions such as type 2 diabetes or high blood pressure.<\/p>\n<p>The introduction of pill versions of these medications offers the potential for increased patient adherence. Many individuals \u2064may feel reluctant to \u2064use injectable medications, \u2062resulting in noncompliance and decreased efficacy. With the\u200b availability of oral options, more individuals struggling \u2063with obesity may be willing to try these medications and experience the benefits\u2063 they can \u2062provide.<\/p>\n<p>In addition to the convenience of pill \u2062administration, the cost-effectiveness of\u2063 these oral medications will likely attract a larger patient \u2063population. With a simpler chemical structure and easier manufacturing \u2062process, pharmaceutical companies can produce these pills at \u2063a lower cost, making them more affordable to\u200d patients.\u200d This affordability will be particularly valuable in regions with limited access to refrigeration, where injectable medications may be less\u200d practical.<\/p>\n<p>Despite the \u2062advancements in weight loss medication development, \u2063it \u200cis important to note that these pills are not a magic solution\u200d for obesity. They are\u200d most effective when used \u200cas part of a comprehensive \u200bweight loss program that includes diet, exercise, and behavioral changes. Additionally, like\u2064 any medication, they may have potential side effects that should be closely monitored by healthcare professionals.<\/p>\n<p>The race among\u200d pharmaceutical giants to develop pill versions \u2062of weight loss medications demonstrates the growing demand \u2064for more\u2064 accessible and effective obesity treatments. Novo Nordisk and Eli Lilly&#8217;s progress\u200c in the\u2062 clinical trials of semaglutide and orforglipron \u2062show promising results \u2064and offer hope for millions of \u200dindividuals struggling with weight management.<\/p>\n<p>As these medications move closer to approval\u200d and release, it\u200c will \u2063be \u200bcrucial for healthcare providers and patients to carefully evaluate their benefits and potential \u2064risks. Education and awareness regarding\u2064 safe and effective use are essential\u200d to\u200b ensure that these pills \u200bare utilized as part\u2064 of\u200b a comprehensive approach to obesity treatment.<\/p>\n<p>In conclusion, the \u2064development of pill versions of\u2062 weight loss medications by pharmaceutical giants is an exciting advancement in the field of obesity treatment. The potential benefits of increased\u2064 patient adherence, cost-effectiveness, and ease of production make these oral \u2063options a welcome\u200c addition to the range\u200d of\u200b treatments available for obesity. \u2063While further research and evaluation are needed, these\u200d pills hold promise\u2064 in addressing the global obesity epidemic and improving the health and well-being of individuals struggling with excess weight.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pharmaceutical giants Novo Nordisk and Eli Lilly are projecting that pill versions of their coveted weight loss medications could come to market as soon as next year, increasing treatment options for obesity. Novo&#8217;s semaglutide and Lilly&#8217;s orforglipron pills are both in stage three of clinical trials and have shown promising results. Both pills function similarly<\/p>\n","protected":false},"author":1,"featured_media":2102091,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","fifu_image_alt":"","footnotes":""},"categories":[],"tags":[],"class_list":["post-2102090","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","_links":{"self":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/2102090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/comments?post=2102090"}],"version-history":[{"count":0,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/2102090\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media\/2102091"}],"wp:attachment":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media?parent=2102090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/categories?post=2102090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/tags?post=2102090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}